Combination autologous stem cell therapy - TCA Cellular Therapy

Drug Profile

Combination autologous stem cell therapy - TCA Cellular Therapy

Alternative Names: MESENDO

Latest Information Update: 29 Jun 2015

Price : $50

At a glance

  • Originator TCA Cellular Therapy
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ischaemia; Ischaemic heart disorders

Most Recent Events

  • 25 Aug 2011 Phase-II development is completed for Ischaemia (of the lower limb) in USA
  • 27 Apr 2011 TCA Cellular Therapy completes enrolment in its phase II trial for Ischaemic heart disorders in USA (NCT00790764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top